ENOrphanet Journal of Rare Diseases | EU should adopt US orphan drug incentives to enhance competitiveness
Date: March 20, 2025
Classification: Frontiers
Recommend:
The article systematically analyzes US orphan drug incentive mechanisms and proposes EU adoption of similar measures to enhance orphan drug R&D competitiveness.
Literature Overview
This article 'The EMA as a potential driver of competitiveness of orphan medicines in Europe: a focus on regulatory incentives and funding opportunities' published in Orphanet Journal of Rare Diseases reviews US success in orphan drug incentives including Priority Review Vouchers (PRV), Orphan Drug Grant Programs, and Rare Disease Evidence-Development Plan (RDEP) process. It explores their applicability in the EU context while emphasizing the European Medicines Agency's (EMA) potential role in enhancing EU orphan drug market competitiveness.
Background Knowledge
Orphan drugs target rare diseases but face development challenges due to small market sizes. The US implemented its Orphan Drug Act in 1983 with 7-year market exclusivity and 6-month pediatric extension, significantly boosting orphan drug development. In contrast, the EU's current incentives are weaker, causing most orphan drugs to first gain approval in the US. This article focuses on FDA's successful mechanisms like PRV, grant programs, and RDEP process, discussing their applicability in the EU. Current EU pharmaceutical legislation revisions aim to improve competitiveness in orphan drug development. Challenges include longer approval timelines, difficulties in clinical trial recruitment, and insufficient grant mechanisms. Proposed solutions include establishing European Accelerated Assessment Vouchers (EAAV) and enhancing EMA's funding role for orphan drugs.
Research Methods and Experiments
The article evaluates FDA's orphan drug incentive effectiveness through literature analysis and data comparison, covering PRV programs, orphan drug grants, and RDEP process. It compares EU-US differences in orphan drug approvals, clinical trial numbers, and review timelines, proposing the feasibility of European Accelerated Assessment Vouchers (EAAV) based on EMA's current accelerated review mechanisms. Additionally, it analyzes EMA's role in orphan drug funding and natural history studies, suggesting adoption of FDA models to enhance clinical trial attractiveness.
Key Conclusions and Perspectives
Research Implications and Future Directions
The article suggests EU should adopt US practices by establishing EAAV, enhancing EMA's funding for clinical trials and natural history studies to improve orphan drug R&D competitiveness. Future initiatives could include EMA-led grant mechanisms and flexible review processes similar to RDEP to attract companies to prioritize EU for orphan drug development.
Conclusion
This article systematically analyzes US orphan drug development incentives including Priority Review Vouchers (PRV), Orphan Drug Grant Programs, and RDEP process. These measures significantly enhanced US attractiveness in orphan drug development, leading to earlier approvals. In contrast, EU's current incentives are weaker with longer approval timelines and lack of direct grants. The article recommends EU establish EMA-led European Accelerated Assessment Voucher (EAAV) mechanisms, provide clinical trial grants, and implement flexible review processes similar to RDEP. These measures could enhance EU orphan drug competitiveness, attract companies to prioritize Europe, improve patient access, and boost biomedical industries. These reforms align with new EU pharmaceutical legislation and merit further exploration.
